Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;101(4):371-385.
doi: 10.1111/cen.15009. Epub 2023 Dec 21.

Rare forms of congenital adrenal hyperplasia

Affiliations
Review

Rare forms of congenital adrenal hyperplasia

Busra Gurpinar Tosun et al. Clin Endocrinol (Oxf). 2024 Oct.

Abstract

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders due to pathogenic variants in genes encoding enzymes and cofactors involved in adrenal steroidogenesis. Although 21-hydroxylase, 11β-hydroxylase, 3β-hydroxysteroid dehydrogenase type 2, 17α-hydroxylase/17,20-lyase, P450 oxidoreductase, steroidogenic acute regulatory protein, cholesterol side-chain cleavage enzyme deficiencies are considered within the definition of CAH, the term 'CAH' is often used to refer to '21-hydroxylase deficiency (21OHD)' since 21OHD accounts for approximately 95% of CAH in most populations. The prevalence of the rare forms of CAH varies according to ethnicity and geographical location. In most cases, the biochemical fingerprint of impaired steroidogenesis points to the specific subtypes of CAH, and genetic testing is usually required to confirm the diagnosis. Despite there are significant variations in clinical characteristics and management, most data about the rare CAH forms are extrapolated from 21OHD. This review article aims to collate the currently available data about the diagnosis and the management of rare forms of CAH.

Keywords: 11β‐hydroxylase deficiency; 17α‐hydroxylase deficiency; 3β‐hydroxysteroid dehydrogenase type 2 deficiency; P450 oxidoreductase deficiency; cholesterol side‐chain cleavage enzyme deficiency; steroidogenic acute regulatory protein deficiency.

PubMed Disclaimer

References

REFERENCES

    1. Claahsen‐van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia‐current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43(1):91‐159.
    1. White PC, White PC, Speiser PW. Congenital adrenal hyperplasia due to 21‐hydroxylase deficiency. Endocr Rev. 2000;21(3):245‐291.
    1. Hannah‐Shmouni F, Chen W, Merke DP. Genetics of congenital adrenal hyperplasia. Endocr Metab Clin North Am. 2017;46(2):435‐458.
    1. Yildiz M, Isik E, Abali ZY, et al. Clinical and hormonal profiles correlate with molecular characteristics in patients with 11β‐hydroxylase deficiency. J Clin Endocrinol Metabol. 2021;106(9):e3714‐e3724.
    1. Güran T, Tezel B, Çakır M, et al. Neonatal screening for congenital adrenal hyperplasia in Turkey: outcomes of extended pilot study in 241,083 infants. J Clin Res Pediatr Endocrinol. 2020;12(3):287‐294.

MeSH terms

Supplementary concepts

LinkOut - more resources